![[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth](https://www.europesays.com/ch/wp-content/uploads/2026/02/84b0110bbf60eb8397db0461bc3549c4-380x220.png)
European Commission approves Roche’s Lunsumio subcutaneous for relapsed or refractory follicular lymphoma
F. Hoffmann-La Roche Ltd Lunsumio provides high rates of deep and long-lasting responses in third-line and later follicular…
Browsing Tag